The latest price target for Biohaven (NYSE:BHVN) was reported by Deutsche Bank on February 11, 2025. The analyst firm set a price target for $65.00 expecting BHVN to rise to within 12 months (a possible 102.74% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Biohaven (NYSE:BHVN) was provided by Deutsche Bank, and Biohaven initiated their buy rating.

There is no last upgrade for Biohaven

The last downgrade for Biohaven Ltd happened on August 19, 2022 when Piper Sandler changed their price target from N/A to N/A for Biohaven Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biohaven, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biohaven was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.

While ratings are subjective and will change, the latest Biohaven (BHVN) rating was a initiated with a price target of $0.00 to $65.00. The current price Biohaven (BHVN) is trading at is $32.06, which is within the analyst’s predicted range.